289 related articles for article (PubMed ID: 31819423)
21. Enhanced oral bioavailability of insulin using PLGA nanoparticles co-modified with cell-penetrating peptides and Engrailed secretion peptide (Sec).
Zhu S; Chen S; Gao Y; Guo F; Li F; Xie B; Zhou J; Zhong H
Drug Deliv; 2016 Jul; 23(6):1980-91. PubMed ID: 26181841
[TBL] [Abstract][Full Text] [Related]
22. Gastrointestinal stability, physicochemical characterization and oral bioavailability of chitosan or its derivative-modified solid lipid nanoparticles loading docetaxel.
Shi LL; Lu J; Cao Y; Liu JY; Zhang XX; Zhang H; Cui JH; Cao QR
Drug Dev Ind Pharm; 2017 May; 43(5):839-846. PubMed ID: 27487431
[TBL] [Abstract][Full Text] [Related]
23. Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis.
Chokshi NV; Khatri HN; Patel MM
Drug Dev Ind Pharm; 2018 Dec; 44(12):1975-1989. PubMed ID: 30058392
[TBL] [Abstract][Full Text] [Related]
24. Novel Solid Lipid Nanoparticle with Endosomal Escape Function for Oral Delivery of Insulin.
Xu Y; Zheng Y; Wu L; Zhu X; Zhang Z; Huang Y
ACS Appl Mater Interfaces; 2018 Mar; 10(11):9315-9324. PubMed ID: 29484890
[TBL] [Abstract][Full Text] [Related]
25. Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: optimization,
Patel MH; Mundada VP; Sawant KK
Drug Dev Ind Pharm; 2019 Aug; 45(8):1242-1257. PubMed ID: 30880488
[No Abstract] [Full Text] [Related]
26. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables.
Das S; Ng WK; Kanaujia P; Kim S; Tan RB
Colloids Surf B Biointerfaces; 2011 Nov; 88(1):483-9. PubMed ID: 21831615
[TBL] [Abstract][Full Text] [Related]
27. Solid lipid nanoparticles for the controlled delivery of poorly water soluble non-steroidal anti-inflammatory drugs.
Kumar R; Singh A; Garg N; Siril PF
Ultrason Sonochem; 2018 Jan; 40(Pt A):686-696. PubMed ID: 28946474
[TBL] [Abstract][Full Text] [Related]
28. Development and characterization of Brigatinib loaded solid lipid nanoparticles: In-vitro cytotoxicity against human carcinoma A549 lung cell lines.
Ahmed MM; Fatima F; Anwer MK; Aldawsari MF; Alsaidan YSM; Alfaiz SA; Haque A; Az A; Alhazzani K
Chem Phys Lipids; 2020 Nov; 233():105003. PubMed ID: 33096096
[TBL] [Abstract][Full Text] [Related]
29. Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: Pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Eur J Pharm Biopharm; 2017 Jan; 110():47-57. PubMed ID: 27810472
[TBL] [Abstract][Full Text] [Related]
30. Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system.
Chalikwar SS; Belgamwar VS; Talele VR; Surana SJ; Patil MU
Colloids Surf B Biointerfaces; 2012 Sep; 97():109-16. PubMed ID: 22609590
[TBL] [Abstract][Full Text] [Related]
31. Solid lipid nanoparticles as insulin inhalation carriers for enhanced pulmonary delivery.
Bi R; Shao W; Wang Q; Zhang N
J Biomed Nanotechnol; 2009 Feb; 5(1):84-92. PubMed ID: 20055110
[TBL] [Abstract][Full Text] [Related]
32. Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers. I. Effect of formulation variables on the physicochemical properties, drug release and stability of clotrimazole-loaded nanoparticles.
Das S; Ng WK; Tan RB
Nanotechnology; 2014 Mar; 25(10):105101. PubMed ID: 24531790
[TBL] [Abstract][Full Text] [Related]
33. Biodistribution and pharmacokinetics of thiolated chitosan nanoparticles for oral delivery of insulin in vivo.
Sudhakar S; Chandran SV; Selvamurugan N; Nazeer RA
Int J Biol Macromol; 2020 May; 150():281-288. PubMed ID: 32057846
[TBL] [Abstract][Full Text] [Related]
34. Fabrication and Characterization of Pectin Films Containing Solid Lipid Nanoparticles for Buccal Delivery of Fluconazole.
Hirun N; Mahadlek J; Limmatvapirat S; Sriamornsak P; Yonemochi E; Furuishi T; Kraisit P
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791451
[TBL] [Abstract][Full Text] [Related]
35. Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis.
Vieira ACC; Chaves LL; Pinheiro S; Pinto S; Pinheiro M; Lima SC; Ferreira D; Sarmento B; Reis S
Int J Pharm; 2018 Jan; 536(1):478-485. PubMed ID: 29203137
[TBL] [Abstract][Full Text] [Related]
36. Solid lipid nanoparticles for thermoresponsive targeting: evidence from spectrophotometry, electrochemical, and cytotoxicity studies.
Rehman M; Ihsan A; Madni A; Bajwa SZ; Shi D; Webster TJ; Khan WS
Int J Nanomedicine; 2017; 12():8325-8336. PubMed ID: 29200845
[TBL] [Abstract][Full Text] [Related]
37. Enhanced oral bioavailability of insulin-loaded solid lipid nanoparticles: pharmacokinetic bioavailability of insulin-loaded solid lipid nanoparticles in diabetic rats.
Ansari MJ; Anwer MK; Jamil S; Al-Shdefat R; Ali BE; Ahmad MM; Ansari MN
Drug Deliv; 2016 Jul; 23(6):1972-9. PubMed ID: 26017100
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design.
Dudhipala N; Veerabrahma K
Drug Dev Ind Pharm; 2015; 41(12):1968-77. PubMed ID: 25830370
[TBL] [Abstract][Full Text] [Related]
39. Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery.
Rawat MK; Jain A; Mishra A; Muthu MS; Singh S
Ther Deliv; 2010 Jul; 1(1):63-73. PubMed ID: 22816120
[TBL] [Abstract][Full Text] [Related]
40. Enhanced intestinal absorption of asenapine maleate by fabricating solid lipid nanoparticles using TPGS: elucidation of transport mechanism, permeability across Caco-2 cell line and in vivo pharmacokinetic studies.
Patel M; Mundada V; Sawant K
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):144-153. PubMed ID: 30669881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
